TregTherapeutics is developing targeted therapies that modulate immune responses to treat and potentially cure multiple sclerosis by focusing on the autoimmune mechanisms that drive the disease's progression. The company's preclinical approach aims to provide a more effective treatment option for patients suffering from this debilitating neurological condition.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for autoimmune diseases often rely on broad immunosuppression, which can lead to increased susceptibility to infections and other adverse effects. These treatments manage symptoms but do not address the underlying autoimmune response, leaving patients with a need for more targeted and curative therapies.
Solution
TregTherapeutics is developing the TILAC™ (Tolerance Induction by Linked Adjuvant/Cytokine conjugant) platform, a novel approach to induce tolerance in autoimmune diseases. TILAC™ utilizes a unique conjugate of a vaccine adjuvant and an anti-inflammatory cytokine to create a tolerogenic microenvironment. This microenvironment promotes the expansion of regulatory T cells (Tregs) specific to the self-antigens driving the autoimmune response, re-establishing immune homeostasis without the need for broad immunosuppression. The platform is designed to harness the body's own endogenous pathogenic antigens to down-regulate the immune response associated with a particular disease, offering a potentially universal application across a range of autoimmune conditions.
Target Audience
The primary target audience includes individuals suffering from autoimmune diseases such as multiple sclerosis, plaque psoriasis, rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, systemic lupus erythematosus, and other immuno-inflammatory conditions.
Features
- TILAC™ platform leverages a linked adjuvant/cytokine conjugate to induce tolerance.
- Targets pathogenic self-antigens without requiring their identification in advance.
- Designed to create a robust tolerogenic microenvironment for sustained immune modulation.
- Aims to expand regulatory T cells (Tregs) to down-regulate inflammatory responses.
- Does not require extracorporeal manipulation of tissue or cellular components.
- Intended as a potentially universal therapy applicable to a range of autoimmune diseases.